Want to see JP:7649 full AI Analyst Report?
Top Page
Sugi Holdings Co
(7649)
Select Model
Select Model
Rating:62Neutral
Price Target:
¥1,400.00
▼(-51.89% Downside)
Action:Reiterated
Date:08/29/26
The score is driven primarily by solid financial performance (strong revenue growth and improved 2026 cash generation) tempered by rising leverage and historically volatile cash flow. Technical signals are a key drag, as the stock trades below major moving averages with negative MACD, while valuation is moderately supportive via a mid-teens P/E and a ~2.65% dividend yield.
Positive Factors
Strong multi-year revenue growth
Sustained revenue expansion indicates continuing demand for Sugi’s drugstore, pharmacy, healthcare, and daily-needs offerings. Growth across several years provides a durable base for store productivity, purchasing scale, and further customer penetration.
Negative Factors
Material increase in leverage
The step-up in debt changes the company’s historically conservative financial profile and raises exposure to interest costs and refinancing needs. Higher leverage could constrain strategic flexibility if expansion requires sustained investment or cash flow weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong multi-year revenue growth
Sustained revenue expansion indicates continuing demand for Sugi’s drugstore, pharmacy, healthcare, and daily-needs offerings. Growth across several years provides a durable base for store productivity, purchasing scale, and further customer penetration.
Read all positive factors
Sugi Holdings Co (7649) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥259.17B
Dividend Yield2.65%
Average Volume (3M)634.13K
Price to Earnings (P/E)15.6
Beta (1Y)0.25
Revenue Growth12.20%
EPS Growth-25.42%
CountryJP
Employees13,417
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)84.70
Shares Outstanding195,074,510
10 Day Avg. Volume884,930
30 Day Avg. Volume634,130
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.24
Price to Sales (P/S)0.64
P/FCF Ratio10.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,386.67Price Target Upside16.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)89.7
Revenue Forecast (FY)¥1.10T
Sugi Holdings Co Business Overview & Revenue Model
Company Description
Sugi Holdings Co.,Ltd. operates drugstores in Japan. The company also provides self-care support services, including meal delivery, cancer and other health checkups, specific health guidance, health information, and community comprehensive agreeme...
How the Company Makes Money
Sugi Holdings primarily earns revenue through (1) retail sales at its drugstores and (2) prescription dispensing services at in-store (or adjacent) pharmacies. Retail revenue is generated from the sale of over-the-counter pharmaceuticals, cosmetic...
Sugi Holdings Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
62
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Feb 2026 | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04T | 1.01T | 878.02B | 744.48B | 667.65B | 625.48B |
| Gross Profit | 328.93B | 321.20B | 275.04B | 228.84B | 202.52B | 191.49B |
| EBITDA | 66.73B | 66.16B | 56.18B | 46.24B | 40.56B | 38.74B |
| Net Income | 30.66B | 44.98B | 25.69B | 21.98B | 19.01B | 19.39B |
Balance Sheet | ||||||
| Total Assets | 638.46B | 614.49B | 495.12B | 391.99B | 353.25B | 336.38B |
| Cash, Cash Equivalents and Short-Term Investments | 124.63B | 111.21B | 52.79B | 47.43B | 70.64B | 71.83B |
| Total Debt | 92.88B | 94.04B | 47.72B | 2.76B | 1.95B | 2.31B |
| Total Liabilities | 344.53B | 324.02B | 244.41B | 158.62B | 136.71B | 122.49B |
| Stockholders Equity | 293.91B | 290.46B | 250.70B | 233.36B | 216.54B | 213.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 63.69B | 13.31B | 8.21B | 20.09B | -13.57B |
| Operating Cash Flow | 0.00 | 86.78B | 36.94B | 39.04B | 38.28B | 7.17B |
| Investing Cash Flow | 0.00 | -69.64B | -33.28B | -30.98B | -23.26B | -23.89B |
| Financing Cash Flow | 0.00 | 41.21B | 11.63B | -5.28B | -14.21B | -5.29B |
Sugi Holdings Co Technical Analysis
Negative
2910.00
Price Trends
1456.11
Negative
1507.07
Negative
1644.53
Negative
Market Momentum
-30.61
Positive
36.36
Neutral
18.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7649, the sentiment is Negative. The current price of 2910 is above the 20-day moving average (MA) of 1369.97, above the 50-day MA of 1456.11, and above the 200-day MA of 1644.53, indicating a bearish trend. The MACD of -30.61 indicates Positive momentum. The RSI at 36.36 is Neutral, neither overbought nor oversold. The STOCH value of 18.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7649.
Sugi Holdings Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥214.94B | 12.97 | ― | 2.35% | 8.76% | 8.19% | |
69 Neutral | ¥435.31B | 13.90 | 11.29% | 3.42% | 4.32% | 0.18% | |
69 Neutral | ¥522.89B | 16.14 | ― | 1.28% | 8.72% | 3.45% | |
64 Neutral | ¥1.07T | 18.22 | 7.67% | 2.04% | ― | ― | |
62 Neutral | ¥259.17B | 15.60 | 10.75% | 1.20% | 12.20% | -25.42% | |
54 Neutral | ¥391.74B | 23.67 | ― | 0.41% | 13.04% | -0.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7649
Sugi Holdings Co
1,321.00
-521.19
-28.29%
JP:9989
Sundrug Co
3,740.00
-784.56
-17.34%
JP:3391
TSURUHA Holdings
2,343.50
134.51
6.09%
JP:3148
Create SD Holdings Co., Ltd.
3,410.00
97.61
2.95%
JP:3349
COSMOS Pharmaceutical Corporation
6,524.00
-2,190.66
-25.14%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,196.00
303.18
7.79%
Sugi Holdings Co Corporate Events
Sugi Holdings Boosts Store Network as Prescription Sales Drive July Growth
Aug 14, 2026
Sugi Holdings Co. reported that in July 2026, the Sugi Pharmacy Group opened eight new stores across several prefectures, bringing its total network to 2,353 locations at month-end. The expansion underscores the company’s continued push to g...
SUGI Holdings Raises ¥16.2 Billion via GIC Share Allotment, Boosts Capital and Share Count
Jul 27, 2026
SUGI Holdings Co., Ltd. has completed payment for a third-party allotment of 5,082,000 new shares to Singapore-based institutional investor GIC Private Limited at an issue price of 3,195 yen per share, raising approximately 16.2 billion yen. The t...
Sugi Holdings Posts June Sales Growth on Strong Prescription Business
Jul 15, 2026
In its June 2026 monthly sales bulletin for the fiscal year ending February 2027, Sugi Holdings reported that existing‑store sales at Sugi Pharmacy rose 2.0% year on year, driven by an 11.4% increase in the Prescription Business, which more ...
Sugi Holdings Grows Sales but Forecasts Profit Decline as It Plans Stock Split and New Subsidiary
Jul 9, 2026
Sugi Holdings reported a 10.1% year-on-year rise in net sales to ¥270.2 billion for the quarter ended May 31, 2026, with operating profit up 10.9% to ¥12.2 billion and EBITDA up 7.9%, while profit attributable to owners of the parent plu...
Sugi Holdings taps GIC in ¥16 billion share issue to fund healthcare growth
Jul 9, 2026
Sugi Holdings has approved a third-party allotment of 5,082,000 new shares to GIC Private Limited at ¥3,195 per share, raising about ¥16 billion net to strengthen its balance sheet. The move is intended to fund discontinuous growth, incl...
Sugi Holdings Completes Treasury Stock Disposition for Restricted Stock Compensation
Jun 15, 2026
Sugi Holdings has completed the payment procedures for a previously approved disposition of treasury stock to be used as restricted stock remuneration. The transaction involves issuing 34,219 shares of common stock at ¥2,991 per share, for a ...
Sugi Holdings Posts Strong May Sales and Expands Store Network
Jun 15, 2026
Sugi Holdings reported that in May 2026, existing-store sales at Sugi Pharmacy rose 6.4% year on year, driven by a 6.6% increase in the drugstore segment and a 5.8% gain in the prescription business. On an all-store basis, which reflects network e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.